查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1418675

全球伴隨診斷 (CDx) 市場:2024-2034

Companion Diagnostics (CDx) Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 307 Pages | 商品交期: 最快1-2個工作天內

價格

到 2034 年，全球伴隨診斷 (CDx) 市場規模預計將以 11% 的複合年增長率成長。

CDx 市場的擴張主要得益於科技的發展。這些發展正在催生更好、更靈敏、更有針對性的伴隨診斷測試。下一代定序 (NGS)、液體活檢和人工智慧等技術的改進正在對伴隨診斷行業產生重大影響，預計將在未來幾年推動市場擴張。由於這些改進，伴隨診斷測試變得更加準確、靈敏且成本更低，在個人化醫療中發揮越來越重要的作用。

該報告調查了全球伴隨診斷（CDx）市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析以及競爭格局。各大公司。

目錄

第 1 章報告概述

第 2 章執行摘要

第三章市場概況

  • 主要發現
  • 市場動態
    • 市場驅動力
    • 市場制約因素
    • 市場機會
  • COVID-19 影響分析
  • 波特五力分析
  • PEST分析

第 4 章 伴隨診斷 (CDx) 市場分析:依產品/服務

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 檢測試劑盒和試劑
  • 軟件服務
    • 市場規模趨勢與預測:按地區
    • 市佔率:按地區

第五章伴隨診斷 (CDx) 市場分析:依適應症分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 癌症
  • 感染
  • 心血管疾病
  • 神經系統疾病
  • 其他
    • 市場規模趨勢與預測:按地區
    • 市佔率:按地區

第六章伴隨診斷 (CDx) 市場分析:依技術分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 聚合□鍊式反應 (PCR)
  • 下一代定序（NGS）
  • 原位雜交 (ISH)
  • 免疫組織化學 (IHC)
  • 其他技術
    • 市場規模趨勢與預測:按地區
    • 市佔率:按地區

第 7 章 伴隨診斷 (CDx) 市場分析:按最終用戶

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 製藥和生物製藥公司
  • 參考實驗室
  • 合約研究組織（CRO）
  • 其他
    • 市場規模趨勢與預測:按地區
    • 市佔率:按地區

第 8 章伴隨診斷 (CDx) 市場分析:按地區

  • 主要發現
  • 市場規模趨勢和預測

第九章北美伴隨診斷（CDx）市場分析

第10章歐洲伴隨診斷（CDx）市場分析

第十一章亞太地區伴隨診斷 (CDx) 市場分析

第十二章拉丁美洲伴隨診斷（CDx）市場分析

第十三章中東與非洲伴隨診斷（CDx）市場分析

第十四章公司簡介

  • 戰略視角
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Abbott
  • Almac Group
  • Danaher Corporation
  • Illumina, Inc.
  • bioMerieux
  • Myriad Genetics, Inc.
  • Sysmex Corporation
  • Guardant Health

第十五章 一般性意見/建議

  • Visiongain 的一般討論
  • 對參與企業的建議
Product Code: PHA1312

The global Companion Diagnostics (CDx) market is projected to grow at a CAGR of 11% by 2034.

“The Companion Diagnostics (CDx) Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will be useful for companies that want to expand into different industries or their existing operations in a new region.

Technological Improvements in the CDx Market

The market for CDx is expanding thanks in large part to technological developments. Better, more sensitive, and more focused CDx tests are coming from these developments. Important technical developments in CDx include the following:

  • Next-generation sequencing (NGS): Entire tumour genomes can be sequenced using NGS, a high-throughput sequencing technology. This data can be used to pinpoint genetic mutations that particular medications can target.
  • Liquid biopsy: A less intrusive procedure that can identify cancer cells and other indicators in the circulation is liquid biopsy. This test can be used to track the course of cancer and the effectiveness of treatment and is less intrusive than conventional tissue biopsies.
  • AI (artificial intelligence): AI is being used to create computer algorithms capable of analysing enormous amounts of CDx data. This information can be utilised to spot patterns and forecast patient outcomes.

These technological improvements are having a significant impact on the CDx industry and are projected to fuel market expansion in the coming years. CDx tests are getting more accurate, sensitive, and inexpensive as a result of these improvements, and they are playing an increasingly essential role in personalised medicine.

In 2023, a number of significant businesses plan to make significant investments in companion diagnostics. Here are few instances:

  • Roche: With a strong emphasis on cancer, Roche is a prominent player in the companion diagnostics (CDx) market. The business has created a number of complementary diagnostics for its targeted cancer treatments, including Zelboraf and Herceptin.
  • Another significant participant in the companion diagnostics business is Abbott Laboratories. The Clariscan companion diagnostic test from the company assists in forecasting a patient's reaction to the chemotherapy medication irinotecan.
  • Thermo Fisher Scientific: This top supplier of tools and supplies for companion diagnostic testing is Thermo Fisher Scientific. Several firms are developing companion diagnostic tests using the company's Ion Torrent NGS platform.

Hence, these improvements and new product introductions highlight the CDx market's dynamic nature and its potential to revolutionise cancer therapy by providing precision medicine.

High Capital Investment and Low Cost-benefit Ratio Likely to Challenge Industry Growth

These specialised tests require significant capital expenditure to design and validate. Companion diagnostics, in contrast to more general diagnostic instruments, serve a specific and narrower population. This indicates that the market may not be as large as expected, which would make it difficult to recover the high expenses associated with R&D and obtaining necessary permits. These tests also frequently need for advanced infrastructure and technologies, which raises the cost even further.

The development and validation of these specialised tests necessitates substantial capital commitment. Companion diagnostics, as opposed to broader diagnostic instruments, target a smaller, more specific group. As a result, the market size may be limited, making it difficult to recoup the significant expenditures of research, development, and regulatory approvals. Furthermore, these examinations frequently necessitate expensive technology and infrastructure, which increases the budgetary load.

However, calculating the cost-benefit ratio might be difficult. Companion diagnostics have the potential to improve treatment efficacy and reduce waste by ensuring that the right patients receive the proper treatment. This can result in cost reductions for healthcare systems as well as better patient outcomes. However, realising these benefits is contingent on a number of circumstances, including the prevalence of the targeted group, the efficacy of the companion medication, and the cost of the test itself.

When the target population is small or the diagnostic cost is high, the cost-benefit ratio may be skewed to the negative. Manufacturers may be discouraged from investing in companion diagnostics, even if they provide great therapeutic value.

What Questions Should You Ask Before Buying a Market Research Report?

  • How is the companion diagnostics (CDx) market evolving?
  • What is driving and restraining companion diagnostics (CDx) market?
  • How will each companion diagnostics (CDx) submarket segment grow over the forecast period, and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each companion diagnostics submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading companion diagnostics (CDx) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034, and which geographical region will lead the market in 2034?
  • Who are the leading players, and what are their prospects over the forecast period?
  • What are the companion diagnostics (CDx) projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of companion diagnostics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialization to further scale companion diagnostics (CDx) market?
  • Where is the companion diagnostics (CDx) market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Companion Diagnostics (CDx) Market today, and over the next 10 years:

  • Our 307-page report provides 100 tables and 170 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Companion Diagnostics (CDx) Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Companion Diagnostics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product & Services

  • Assays, Kits & Reagents
  • Software & Services

Technology

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Other Technologies

Indication

  • Cancer
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other Indications

End-users

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations (CROs)
  • Other End-users

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and the U.S., China, U.K., India, and Brazil leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Companion Diagnostics (CDx) Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading Companies profiled in the report:

  • Abbott
  • Agilent Technologies, Inc.
  • Almac Group
  • bioMerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Overall world revenue for Companion Diagnostics (CDx) Market, 2024 to 2034 in terms of value the market will surpass US$6,500 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Companion Diagnostics (CDx) Market, 2024 to 2034” report help you?

In summary, our 300+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Companion Diagnostics (CDx) Market, 2024 to 2034, with forecasts for product & services, technology, indication, and end-users each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 16 key national markets - See forecasts for the Companion Diagnostics (CDx) Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for Abbott, Agilent Technologies, Inc., Almac Group, bioMerieux, Danaher Corporation, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Myriad Genetics, Inc,, QIAGEN, Sysmex Corporation, and Thermo Fisher Scientific Inc. and other major companies involved in the Companion Diagnostics (CDx) Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Companion Diagnostics (CDx) Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Companion Diagnostics (CDx) Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Rate of Chronic Illnesses
      • 3.2.1.2 Technological Improvements in the CDx Market
      • 3.2.1.3 Increasing Public Awareness of Personalised Medicine
      • 3.2.1.4 Growing Need for Targeted Therapy
      • 3.2.1.5 Rising Importance of Personalized Medicine
      • 3.2.1.6 Increasing Global Incidence of Cancer
      • 3.2.1.7 Growing Application Areas of Companion Diagnostics
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Serious Issues and Substantial Medical Costs
      • 3.2.2.2 Creating and Approving CDx Tests is a Challenging and Intricate Process.
      • 3.2.2.3 High Capital Investment and Low Cost-benefit Ratio
      • 3.2.2.4 Uncertain Reimbursement Scenario in Different Regions
      • 3.2.2.5 High Cost of Immunotherapy Treatment
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Creating New CDx Tests for Novel Targeted Medicines
      • 3.2.3.2 Favourable Government Policies
      • 3.2.3.3 Expansion into New Geographic Markets
      • 3.2.3.4 Increasing Demand for Next-Generation Sequencing in CDx
      • 3.2.3.5 Growing Significance of Companion Diagnostics in Drug Development
      • 3.2.3.6 Higher Number of Clinical Trials
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter Analysis
  • 3.5 PEST Analysis

4 Companion Diagnostics (CDx) Market Analysis by Product & Services

  • 4.1 Key Findings
  • 4.2 Product & Services Segment: Market Attractiveness Index
  • 4.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
  • 4.4 Assays, Kits & Reagents
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Software & Services
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Companion Diagnostics (CDx) Market Analysis by Indication

  • 5.1 Key Findings
  • 5.2 Indication Segment: Market Attractiveness Index
  • 5.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
  • 5.4 Cancer
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Infectious Disease
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Cardiovascular Diseases
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Neurological Diseases
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Other Indications
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)

6 Companion Diagnostics (CDx) Market Analysis by Technology

  • 6.1 Key Findings
  • 6.2 Technology Segment: Market Attractiveness Index
  • 6.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
  • 6.4 Polymerase Chain Reaction (PCR)
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Next-Generation Sequencing (NGS)
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 In Situ Hybridization (ISH)
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Immunohistochemistry (IHC)
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 6.8 Other Technologies
    • 6.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.8.2 Market Share by Region, 2024 & 2034 (%)

7 Companion Diagnostics (CDx) Market Analysis by End-users

  • 7.1 Key Findings
  • 7.2 End-users Segment: Market Attractiveness Index
  • 7.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
  • 7.4 Pharmaceutical & Biopharmaceutical Companies
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Reference Laboratories
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Contract Research Organizations (CROs)
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Other End-users
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Companion Diagnostics (CDx) Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Companion Diagnostics (CDx) Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Companion Diagnostics (CDx) Market Attractiveness Index
  • 9.3 North America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
  • 9.5 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
  • 9.6 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
  • 9.7 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
  • 9.8 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
  • 9.9 U.S. Companion Diagnostics (CDx) Market Analysis
  • 9.10 Canada Companion Diagnostics (CDx) Market Analysis

10 Europe Companion Diagnostics (CDx) Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Companion Diagnostics (CDx) Market Attractiveness Index
  • 10.3 Europe Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
  • 10.5 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
  • 10.6 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
  • 10.7 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
  • 10.8 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
  • 10.9 Germany Companion Diagnostics (CDx) Market Analysis
  • 10.10 UK Companion Diagnostics (CDx) Market Analysis
  • 10.11 France Companion Diagnostics (CDx) Market Analysis
  • 10.12 Italy Companion Diagnostics (CDx) Market Analysis
  • 10.13 Spain Companion Diagnostics (CDx) Market Analysis
  • 10.14 Rest of Europe Companion Diagnostics (CDx) Market Analysis

11 Asia Pacific Companion Diagnostics (CDx) Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Companion Diagnostics (CDx) Market Attractiveness Index
  • 11.3 Asia Pacific Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
  • 11.6 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
  • 11.7 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
  • 11.8 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
  • 11.9 China Companion Diagnostics (CDx) Market Analysis
  • 11.10 Japan Companion Diagnostics (CDx) Market Analysis
  • 11.11 India Companion Diagnostics (CDx) Market Analysis
  • 11.12 Australia Companion Diagnostics (CDx) Market Analysis
  • 11.13 South Korea Companion Diagnostics (CDx) Market Analysis
  • 11.14 Rest of Asia Pacific Companion Diagnostics (CDx) Market Analysis

12 Latin America Companion Diagnostics (CDx) Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Companion Diagnostics (CDx) Market Attractiveness Index
  • 12.3 Latin America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
  • 12.5 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
  • 12.6 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
  • 12.7 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
  • 12.8 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
  • 12.9 Brazil Companion Diagnostics (CDx) Market Analysis
  • 12.10 Mexico Companion Diagnostics (CDx) Market Analysis
  • 12.11 Rest of Latin America Companion Diagnostics (CDx) Market Analysis

13 MEA Companion Diagnostics (CDx) Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Companion Diagnostics (CDx) Market Attractiveness Index
  • 13.3 MEA Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
  • 13.5 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
  • 13.6 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
  • 13.7 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
  • 13.8 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
  • 13.9 South Africa Companion Diagnostics (CDx) Market Analysis
  • 13.10 GCC Companion Diagnostics (CDx) Market Analysis
  • 13.11 Rest of MEA Companion Diagnostics (CDx) Market Analysis

14 Company Profiles

  • 14.1 Strategic Outlook
  • 14.2 F. Hoffmann-La Roche Ltd
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
      • 14.2.3.1 Net Revenue, 2017-2022
      • 14.2.3.2 R&D, 2017-2022
      • 14.2.3.3 Regional Market Shares, 2022
    • 14.2.4 Product Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 Agilent Technologies, Inc.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 QIAGEN
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2022
      • 14.4.3.2 R&D, 2017-2022
      • 14.4.3.3 Regional Market Shares, 2022
    • 14.4.4 Product Benchmarking
  • 14.5 Thermo Fisher Scientific Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 Regional Market Shares, 2022
    • 14.5.4 Product Benchmarking
  • 14.6 Abbott
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2017-2022
      • 14.6.3.2 R&D, 2017-2022
      • 14.6.3.3 Regional Market Shares, 2022
    • 14.6.4 Product Benchmarking
  • 14.7 Almac Group
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 Danaher Corporation
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2017-2022
      • 14.8.3.2 Regional Market Shares, 2022
    • 14.8.4 Product Benchmarking
  • 14.9 Illumina, Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2017-2022
      • 14.9.3.2 R&D, 2017-2022
      • 14.9.3.3 Regional Market Shares, 2022
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 bioMerieux
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 Regional Market Shares, 2022
    • 14.10.4 Product Benchmarking
  • 14.11 Myriad Genetics, Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2022
      • 14.11.3.2 R&D, 2017-2022
      • 14.11.3.3 Regional Market Shares, 2022
    • 14.11.4 Product Benchmarking
  • 14.12 Sysmex Corporation
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
      • 14.12.3.3 Regional Market Shares, 2022
    • 14.12.4 Product Benchmarking
  • 14.13 Guardant Health
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2022
      • 14.13.3.2 R&D, 2017-2022
      • 14.13.3.3 Regional Market Shares, 2022
    • 14.13.4 Product Benchmarking

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Companion Diagnostics (CDx) Market Snapshot, 2024 & 2034 (US$ Million, AGR %)
  • Table 2 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): "V" Shaped Recovery
  • Table 3 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): "U" Shaped Recovery
  • Table 4 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): "W" Shaped Recovery
  • Table 5 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): "L" Shaped Recovery
  • Table 6 Companion Diagnostic Market Forecast by Product & Services, 2024-2034 (US$ Million, CAGR%)
  • Table 7 Assays, Kits & Reagents Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 8 Software & Services Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 9 Companion Diagnostic Market Forecast by Indication, 2024-2034 (US$ Million, CAGR%)
  • Table 10 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 11 Infectious Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 12 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 13 Neurological Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 14 Other Indications Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 15 Companion Diagnostic Market Forecast by Technology, 2024-2034 (US$ Million, CAGR%)
  • Table 16 PCR Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 17 Next-Generation Sequencing (NGS) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 18 In Situ Hybridization (ISH) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 19 Immunohistochemistry (IHC) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 20 Other Technologies Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 21 Companion Diagnostic Market Forecast by End-users, 2024-2034 (US$ Million, CAGR%)
  • Table 22 Pharmaceutical & Biopharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 23 Reference Laboratories Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Contract Research Organizations (CROs) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 25 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
  • Table 26 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Table 27 North America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 28 North America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Table 29 North America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 30 North America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Table 31 North America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 32 U.S. Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 33 Canada Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 34 Europe Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 35 Europe Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Table 36 Europe Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 37 Europe Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Table 38 Europe Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 39 Germany Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 40 UK Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 41 France Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 42 Italy Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 43 Spain Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 44 Rest of Europe Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 45 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 46 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Table 47 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 48 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Table 49 Asia Pacific Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 50 China Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 51 Japan Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 52 India Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 53 Australia Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 54 South Korea Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 55 Rest of Asia Pacific Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 56 Latin America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 57 Latin America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Table 58 Latin America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 59 Latin America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Table 60 Latin America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 61 Brazil Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 62 Mexico Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 63 Rest of Latin America Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 64 MEA Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 65 MEA Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Table 66 MEA Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 67 MEA Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Table 68 MEA Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 69 South Africa Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 70 GCC Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 71 Rest of MEA Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Table 72 Strategic Outlook
  • Table 73 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 75 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 76 Agilent Technologies, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 Agilent Technologies, Inc.: Product Benchmarking
  • Table 78 Agilent Technologies, Inc.: Strategic Outlook
  • Table 79 QIAGEN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 QIAGEN: Product Benchmarking
  • Table 81 Thermo Fisher Scientific: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Thermo Fisher Scientific.: Product Benchmarking
  • Table 83 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 Abbott: Product Benchmarking
  • Table 85 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Almac Group: Product Benchmarking
  • Table 87 Almac Group: Strategic Outlook
  • Table 88 Danaher Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Danaher Corporation: Product Benchmarking
  • Table 90 Illumina: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Illumina: Product Benchmarking
  • Table 92 Illumina: Strategic Outlook
  • Table 93 bioMerieux: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Biomurieux: Product Benchmarking
  • Table 95 Myriad Genetics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 MYRIAD GENETICS, INC.: Product Benchmarking
  • Table 97 Sysmex Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Sysmex Corporation: Product Benchmarking
  • Table 99 Guardant Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 GUARDANT HEALTH: Product Benchmarking
  •  

List of Figures

  • Figure 1 Companion Diagnostics (CDx) Market Segmentation
  • Figure 2 Companion Diagnostics (CDx) Market by Technology: Market Attractiveness Index
  • Figure 3 Companion Diagnostics (CDx) Market by Indication: Market Attractiveness Index
  • Figure 4 Companion Diagnostics (CDx) Market by Product & Services: Market Attractiveness Index
  • Figure 5 Companion Diagnostics (CDx) Market by End-users: Market Attractiveness Index
  • Figure 6 Companion Diagnostics (CDx) Market Attractiveness Index by Region
  • Figure 7 Companion Diagnostics (CDx) Market: Market Dynamics
  • Figure 8 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 9 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 10 Companion Diagnostic Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 11 Companion Diagnostic Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 12 PEST Analysis of Companion Diagnostic Market
  • Figure 13 Companion Diagnostics (CDx) Market by Product & Services: Market Attractiveness Index
  • Figure 14 Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Figure 15 Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024, 2029, 2034 (%)
  • Figure 16 Assays, Kits & Reagents Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 17 Assays, Kits & Reagents Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 18 Software & Services Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 19 Software & Services Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 20 Companion Diagnostics (CDx) Market by Indication: Market Attractiveness Index
  • Figure 21 Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 22 Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024, 2029, 2034 (%)
  • Figure 23 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 24 Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Infectious Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 26 Infectious Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 28 Cardiovascular Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Neurological Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 30 Neurological Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Other Indications Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 32 Other Indications Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Companion Diagnostics (CDx) Market by Technology: Market Attractiveness Index
  • Figure 34 Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 35 Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024, 2029, 2034 (%)
  • Figure 36 Polymerase Chain Reaction (PCR) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 37 Polymerase Chain Reaction (PCR) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 38 Next-Generation Sequencing (NGS) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 39 Next-Generation Sequencing (NGS) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 40 In Situ Hybridization (ISH) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 41 In Situ Hybridization (ISH) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 42 Immunohistochemistry (IHC) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Immunohistochemistry (IHC) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 44 Other Technologies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Other Technologies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Companion Diagnostics (CDx) Market by End-users: Market Attractiveness Index
  • Figure 47 Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 48 Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024, 2029, 2034 (%)
  • Figure 49 Pharmaceutical & Biopharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 50 Pharmaceutical & Biopharmaceutical Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 51 Reference Laboratories Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 52 Reference Laboratories Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 53 Contract Research Organizations (CROs) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 54 Contract Research Organizations (CROs) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 55 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 56 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 57 Companion Diagnostics (CDx) Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 58 Companion Diagnostics (CDx) Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 59 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 60 North America Companion Diagnostics (CDx) Market Attractiveness Index
  • Figure 61 North America Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 62 North America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 63 North America Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 64 North America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Figure 65 North America Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
  • Figure 66 North America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 67 North America Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 68 North America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 69 North America Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 70 North America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 71 North America Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 72 U.S. Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 73 Canada Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 74 Europe Companion Diagnostics (CDx) Market Attractiveness Index
  • Figure 75 Europe Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 76 Europe Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 77 Europe Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 78 Europe Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Figure 79 Europe Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
  • Figure 80 Europe Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 81 Europe Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 82 Europe Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 83 Europe Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 84 Europe Companion Diagnostics (CDx) Market Forecast by End-user, 2024-2034 (US$ Million, AGR %)
  • Figure 85 Europe Companion Diagnostics (CDx) Market Share Forecast by End-user, 2024 & 2034 (%)
  • Figure 86 Germany Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 87 UK Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 88 France Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 89 Italy Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 90 Spain Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Rest of Europe Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 92 Asia Pacific Companion Diagnostics (CDx) Market Attractiveness Index
  • Figure 93 Asia Pacific Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 94 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 96 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Figure 97 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
  • Figure 98 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 99 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 100 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 101 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 102 Asia Pacific Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 103 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 104 China Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 105 Japan Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 106 India Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 107 Australia Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 108 South Korea Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 109 Rest of Asia Pacific Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 Latin America Companion Diagnostics (CDx) Market Attractiveness Index
  • Figure 111 Latin America Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 112 Latin America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 113 Latin America Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 114 Latin America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Latin America Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
  • Figure 116 Latin America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 117 Latin America Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 118 Latin America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 119 Latin America Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 120 Latin America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 121 Latin America Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 122 Brazil Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 123 Mexico Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Rest of Latin America Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 125 MEA Companion Diagnostics (CDx) Market Attractiveness Index
  • Figure 126 MEA Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 127 MEA Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 128 MEA Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 129 MEA Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
  • Figure 130 MEA Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
  • Figure 131 MEA Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 132 MEA Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 133 MEA Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 134 MEA Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 135 MEA Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 136 MEA Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 137 South Africa Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 138 GCC Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 139 Rest of MEA Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 140 F. Hoffmann-La Roche Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 141 F. Hoffmann-La Roche Ltd: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 142 F. Hoffmann-La Roche Ltd: Regional Market Shares, 2022
  • Figure 143 Agilent Technologies, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 144 Agilent Technologies, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 145 Agilent Technologies, Inc.: Regional Market Shares, 2022
  • Figure 146 QIAGEN: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 147 QIAGEN: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 148 QIAGEN: Regional Market Shares, 2022
  • Figure 149 Thermo Fisher Scientific: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 150 Thermo Fisher Scientific.: Regional Market Shares, 2022
  • Figure 151 Abbott: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 152 Abbott: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 153 Abbott: Regional Market Shares, 2022
  • Figure 154 Danaher Corporation: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 155 Danaher Corporation: Regional Market Shares, 2022
  • Figure 156 Illumina: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 157 Illumina: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 158 Illumina: Regional Market Shares, 2022
  • Figure 159 bioMerieux: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 160 bioMerieux: Regional Market Shares, 2022
  • Figure 161 Myriad Genetics, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 162 Myriad Genetics, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 163 Myriad Genetics, Inc.: Regional Market Shares, 2022
  • Figure 164 Sysmex Corp: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 165 Sysmex Corp: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 166 Sysmex Corp: Regional Market Shares, 2022
  • Figure 167 Guardant Health: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 168 Guardant Health: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 169 GUARDANT HEALTH, INC: Regional Market Shares, 2022